TX-FLUENCE
24.1.2020 12:02:09 CET | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and agriculture production, announced today it is expanding its presence in the Emsland region of Germany through partnerships with growers and other horticulture specialists operating out of Papenburg.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200124005109/en/
Given Papenburg’s decades-long history of attracting horticulture experts, Fluence’s innovative lighting solutions for horticulture are a natural fit for the region’s tomato, cucumber, leafy greens and herb growers.
Forging connections with Papenburg’s horticultural leaders
Elektro Evers , an engineering firm specializing in greenhouse technology, is Fluence’s exclusive systems integrator in the Papenburg region. Elektro Evers assists customers with installing, integrating and maintaining Fluence’s horticulture lighting systems. The company’s managing director, Norbert Bröring, says Fluence’s partnership is well-suited for the region.
“We are excited to collaborate with Fluence and bring the team’s deep horticulture lighting expertise to Papenburg’s growers,” Bröring said. “As an extension of German lighting innovator OSRAM, we know we’ve found the right partner in Fluence. Together, our advanced solutions will empower customers to cultivate plants under optimal conditions while mitigating energy demands.”
Papenburg’s Gartenbauzentrale —a 100-hectare food cooperative representing 49 family farms—recommends Fluence’s LED solutions to help members produce high-quality, consistent herbs and vegetables throughout the year. The energy savings resulting from LED use also enables Gartenbauzentrale members to apply for EU funding granted for resource conservation.
“Our members seek the most innovative, reliable technology for their farms,” said Marco Lüpken, head of controlling for Gartenbauzentrale. “High and consistent product quality as well as year-round predictable yields are key in our business. Fluence’s precise, high-intensity lighting solutions enable our growers to meet and exceed their growth goals efficiently with better-tasting plants.”
Investing in advanced technology: Greenhouse growers capitalize on LEDs
Friedrich Schulz’s 5.5 hectare farm—which grows herbs year-round in addition to lettuce, peppers and chives—utilizes VYPR 2p fixtures with PhysioSpec Greenhouse spectra across 3,000 square meters of lettuce crop.
“Switching from high pressure sodium lights to Fluence’s LED lights doubled our light intensity, leading to faster, more efficient grow cycles,” Schulz said. “The red lettuce grown under Fluence’s technology produced enhanced coloration within the first week alone. Fluence lighting achieves larger, higher quality yields while also keeping us energy efficient.”
For Reiner Borrmann, leveraging VYPR 2p lights with his basil crop yielded more flavorful, intense-tasting basil after replacing his greenhouse’s HPS lighting fixtures. Borrmann’s farm includes 4 hectares of greenhouse space.
“The energy efficiency allows us to grow more compact crops in less time, and the lights help us observe the plants’ natural colors,” Borrmann said.
Fluence’s general manager of EMEA, Timo Bongartz, said that implementing new LED systems is a decisive factor for a grower’s economic success.
“We are delighted to become an integral part of Papenburg’s cultivation ecosystem to enable growers to succeed in an extremely competitive environment,” Bongartz said. “With our horticulture lighting solutions, they are producing higher- and better-quality yields in less time while garnering significant energy savings. We’re delighted to nurture these partnerships through continued collaboration in the region.”
For more information on Fluence and its solutions for commercial agriculture, visit www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates the most powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is the leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit https://fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200124005109/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 13:00:00 CEST | Press release
Partnership includes FIFA tournaments and events from 2031Agreement encompasses both physical and digital collectibles, and for the first time brings the player jersey patch program to international footballPre-match press conferences for the FIFA World Cup Final to take place at Fanatics Fest on Friday, 17 July 2026 In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football tradin
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 11:21:00 CEST | Press release
Poster presented at ESMO Breast Cancer 2026: Exploring health policy and real-world treatment strategies for early-stage HER2-positive breast cancer across Europe. The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
